Deal of the Day — limited-time pharmacy picks!
Celbopag 50mg Tablet

Celbopag 50mg Tablet

Prescription requiredRx Required

Salt Composition: Eltrombopag Olamine

Expiry Date: 01/2028

Special offer

Price on Request

Price on Request

Inclusive of all taxes

▼

7 Tablets of a Strip

About The Product

Hepatitis C, Hepatitis Medicines, Low Red Platelet Count


Description

Celbopag 50mg tablet is a targeted based medicine mostly used In the treatment of hepatitis C and manage low platelet count. The medicine contains thrombopoietin receptor agonist which belongs to the drug class that help increase platelet production.

Its active ingredient is Eltrombopag Olamine. It works by stimulating the bone marrow to produce more platelets.

Doctor prescribed this medication under strict guidance as incorrect dosage and duration may cause serious side effects.

Indication

  • Treatment for hepatitis C and manage low platelet count

Common Side Effects

Every medication has certain side effects. Celbopag 50mg tablet also contains various side effects, consult the doctor if any of these side effects occur:

  • Common cold
  • Cough
  • Respiratory tract infection
  • Back pain
  • High temperature, cough

  • Loss of appetite
  • Hair loss
  • Swelling in feet or hands
  • Headache, dizziness
  • Mouth and throat pain
  • Joint pain

  • Diarrhea, abdominal pain
  • Common cold

Dosage And Duration

  • Doctor prescribed to take Celbopag 50mg tablet on an empty stomach to ensure proper absorption and effectiveness of the medication. The dosage and duration is correctly recommended to the healthcare professional.
  • Improper use may affect the treatment outcomes so it can be taken exactly as guided by the doctor to ensure safe and effective treatment.

Mechanism Of Action

  • Celbopage 50mg is a targeted based medication, it contains thrombopoietin receptor agonist which belongs to the drug class that help increase drug production.
  • It works similarly to the natural hormone thrombopoietin by stimulating the bone marrow to produce more platelets. It is commonly prescribed for conditions where platelet counts are low.

Safety Advice

Alcohol
It is unknown whether it is safe or unsafe but consuming alcohol while taking Celbopag 50mg tablet should be discussed with the doctor.
Driving
Celbopag 50mg tablet may cause dizziness and fatigue, avoid taking the medication while you are on driving.
Pregnancy
Pregnant women should avoid using Celbopag 50mg tablet as it may affect the new born baby. Consult with the healthcare professional for more query.
Breast Feeding
Celbopag 50mg tablet should not be recommended to breast feeding women because the medicine is passed through breast milk which harm the new infant.
Kidney
It is unknown whether Celbopag 50mg tablet cause side effects on kidney function. It is necessary to consult with the doctor if you are a patient with kidney cancer.
Liver
Celbopag 50mg tablet is not recommended for liver patients as the medication disrupts the liver function. For more information consult with the healthcare professional.

Faqs

Celbopag 50mg tablet should be taken once a day, consult the doctor about the proper dosage and duration.

References

  • Kabir, S. R., Asaduzzaman, M., Shahinuzzaman, A. D. A., & Alam, M. T. (2025). Eltrombopag olamine induces apoptosis in human breast adenocarcinoma and hepatocellular carcinoma cells through modulation of multiple apoptotic pathways. Scientific Reports. https://pubmed.ncbi.nlm.nih.gov/41310342/
  • Wang, K., Xu, P., Lu, S., & Yao, B. (2024). Postmarketing safety of eltrombopag olamine: an analysis of the FDA Adverse Event Reporting System (FAERS).
  • Hussar, D. A. (2009). New drugs: C1 inhibitor (human), romiplostim, and eltrombopag olamine. Journal of the American Pharmacists Association, 49(1), 124-127. https://pubmed.ncbi.nlm.nih.gov/22980701/
  • Wang, J., Zhao, Z., Tao, Y., & Lan, Y. (2024). Bioequivalence and Food Effect Assessment of Eltrombopag Olamine Tablets in Healthy Chinese Subjects: An Open, Randomized, Single‐Dose, and Two‐Period Crossover Study. Clinical Pharmacology in Drug Development, 13(11), 1260-1266.
  • Kaduk, J. A., Gindhart, A. M., & Blanton, T. N. (2021). Crystal structure of eltrombopag olamine form I,(C2H8NO) 2 (C25H20N4O4). Powder Diffraction, 36(2), 100-106.

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026